|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:approves
|
gptkb:2007
|
|
gptkbp:atccode
|
N06 BA12
|
|
gptkbp:available_on
|
generic version
|
|
gptkbp:brand
|
gptkb:Vyvanse
|
|
gptkbp:casnumber
|
608137-41-9
|
|
gptkbp:category
|
Category C
|
|
gptkbp:chemical_formula
|
C15 H25 N3 O
|
|
gptkbp:class
|
central nervous system stimulant
|
|
gptkbp:clinical_trial
|
studies for ADHD
studies for binge eating disorder
|
|
gptkbp:contraindication
|
gptkb:Ophthalmology
heart disease
hyperthyroidism
history of drug abuse
|
|
gptkbp:dosage_form
|
gptkb:tablet
gptkb:capsule
30 mg to 70 mg daily
|
|
gptkbp:duration
|
up to 14 hours
|
|
gptkbp:healthcare
|
approved for ADHD and binge eating disorder
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Vyvanse
|
|
gptkbp:ingredients
|
gptkb:lisdexamfetamine
|
|
gptkbp:is_monitored_by
|
gptkb:weight
blood pressure
heart rate
mental health status
|
|
gptkbp:legal_status
|
prescription only
|
|
gptkbp:lifespan
|
approximately 12 hours
|
|
gptkbp:manufacturer
|
gptkb:Shire_Pharmaceuticals
|
|
gptkbp:marketed_as
|
gptkb:Australia
gptkb:Canada
gptkb:European_Union
gptkb:United_States
|
|
gptkbp:metabolism
|
lisdexamfetamine is converted to dextroamphetamine
|
|
gptkbp:patient_population
|
available from healthcare providers
|
|
gptkbp:premiered_on
|
approximately 1 to 2 hours
|
|
gptkbp:related_products
|
gptkb:Concerta
gptkb:Strattera
gptkb:Ritalin
gptkb:Adderall
gptkb:Dexedrine
|
|
gptkbp:requires
|
available from manufacturer
|
|
gptkbp:route_of_administration
|
oral
|
|
gptkbp:side_effect
|
anxiety
nausea
decreased appetite
irritability
insomnia
dry mouth
increased heart rate
|
|
gptkbp:symptoms
|
gptkb:depression
fatigue
sleep disturbances
|
|
gptkbp:used_for
|
treatment of ADHD
treatment of binge eating disorder
|
|
gptkbp:bfsParent
|
gptkb:Shire_plc
|
|
gptkbp:bfsLayer
|
5
|